SEARCH

SEARCH BY CITATION

References

  • 1
    Eichenauer DA, Fuchs M, Borchmann P, et al. Hodgkin's lymphoma: Current treatment strategies and novel approaches. Expert Rev Hematol 2008;1:6373.
  • 2
    Friedman DL, Constine LS. Late effects of treatment for Hodgkin lymphoma. J Natl Compr Cancer Network: JNCCN.2006;4:24957.
  • 3
    Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. NEngl J Med 1998;339:15061514.
  • 4
    Hnatkova M, Mocikova H, Trneny M, et al. The biological environment of Hodgkin's lymphoma and the role of the chemokine CCL17/TARC. Prague Med Rep 2009;110:3541.
  • 5
    Maggio E, van den Berg A, Diepstra A, et al. Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues. Ann Oncol 2002;13 (Suppl 1):5256.
  • 6
    Kuppers R. The biology of Hodgkin's lymphoma. Nat Rev Cancer 2009;9:1527.
  • 7
    Steidl C, Connors JM, Gascoyne RD. Molecular pathogenesis of Hodgkin's lymphoma: Increasing evidence of the importance of the microenvironment. J Clin Oncol 2011;29:18121826.
  • 8
    Aldinucci D, Gloghini A, Pinto A, et al. The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape. J Pathol 2010;221:248263.
  • 9
    Weihrauch MR, Manzke O, Beyer M, et al. Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin's disease: Potential for a prognostic factor. Cancer research.2005;65:55165519.
  • 10
    Niens M, Visser L, Nolte IM, et al. Serum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22. British journal of haematology.2008;140:527536.
  • 11
    Plattel WJ, van den Berg A, Visser L, et al. Plasma thymus and activation-regulated chemokine as an early response marker in classical Hodgkin's lymphoma. Haematologica 2012;97:410415.